Kymera Therapeutics

Update in progress

KYMR (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule degraders that selectively eliminate disease-causing proteins via the body’s natural protein disposal system. Its programs include KT-621, an oral STAT6 degrader in Phase 2b for multiple inflammatory skin and airway diseases; KT-579, an oral IRF5 degrader in Phase 1 for autoimmune conditions; KT-485/SAR447971 (IRAK4) in Phase II; and CDK2 with oncology potential. It has a Sanofi alliance for IRAK4 outside oncology/inflammation. Incorporated 2015, based in Watertown, MA.

Company score

Sentiment: 0.44; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive